Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.41 |
| ▸ | MTOR | P42345 | 5/20 | 0.40 |
| ▸ | ABL1 | P00519 | 4/20 | 0.40 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | HCK | P08631 | 4/20 | 0.40 |
| ▸ | SRC | P12931 | 4/20 | 0.40 |
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.40 |
| ▸ | PRKDC | P78527 | 4/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.40 |
| ▸ | UGCG | Q16739 | 1/20 | 0.39 |
| ▸ | SGK1 | O00141 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22854498 | 0.84 | MTOR (0.41) | JAK2JAK3LRRK2MTORABL1 | |
| SCHEMBL11306 | 0.78 | SRC (0.47) | MTORABL1EGFRHCKSRC | |
| SCHEMBL10811 | 0.78 | SRC (0.57) | MTORABL1EGFRHCKSRC | |
| SCHEMBL130622 | 0.76 | PIK3CB (0.58) | MTORABL1EGFRHCKSRC | |
| SCHEMBL149180 | 0.75 | PIK3CD (0.55) | MTORABL1EGFRHCKSRC | |
| SCHEMBL28893630 | 0.75 | BTK (0.41) | — | |
| SCHEMBL15805251 | 0.74 | CDK9 (0.40) | UGCGCCNT1CDK9CDK2SCN9A | |
| SCHEMBL152637 | 0.73 | PIK3CD (0.49) | LRRK2MTORABL1EGFRHCK | |
| SCHEMBL22854507 | 0.73 | SRC (0.35) | LRRK2MTORABL1EGFRHCK | |
| SCHEMBL17911471 | 0.73 | TNK2 (0.47) | PIK3CBPIK3CGPRKDCPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | claimed |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | disclosed |
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-10-15 | — | — | US | disclosed |
| EP-3444242-A2 | NOVEL BENZOPYRAN KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2019-02-20 | — | — | EP | disclosed |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2016-11-03 | — | — | US | disclosed |
| US-9421209-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2016-08-23 | — | — | US | disclosed |
| EP-3050876-A2 | KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2016-08-03 | — | — | EP | disclosed |
| US-20150174131-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-9018375-B2 | Substituted chromenes as kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2015-04-28 | — | — | US | disclosed |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2014-03-20 | — | — | US | disclosed |
| US-8642607-B2 | 4H-chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2014-02-04 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | PIK3CB, PIK3CD, PDPK1 | JAK2 319/4885JAK3 402/4885LRRK2 303/4885 |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | JAK2 290/4885JAK3 325/4885LRRK2 317/4885 |
| US-20150174131-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | JAK2 280/4885JAK3 383/4885LRRK2 290/4885 |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | JAK2 280/4885JAK3 383/4885LRRK2 290/4885 |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | JAK2 280/4885JAK3 383/4885LRRK2 290/4885 |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | JAK2 280/4885JAK3 383/4885LRRK2 290/4885 |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | JAK2 280/4885JAK3 383/4885LRRK2 290/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | JAK2 170/4885JAK3 432/4885LRRK2 415/4885 |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | JAK2 280/4885JAK3 383/4885LRRK2 290/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | JAK2 280/4885JAK3 383/4885LRRK2 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.